Precipio Inc. (PRPO), a cancer diagnostics company, on Thursday announced its first quarter financial results.
Q1 2026:
The company reported a net loss of $1.4 million, while in the first quarter of 2025, it reported a net loss of $0.9 million.
Revenues reached $6.71 million, an increase from the $4.93 million recorded a year ago. This includes $6.05 million earned in pathology revenue alone.
Adjusted EBITDA was a loss of $0.16 million in the first quarter, amounting to $1.2 per share, compared to the adjusted EBITDA loss of $0.5 million, or $0.5 per share in the previous year.
Non-GAAP adjusted EBITDA showed an EPS of $0.2 per share, compared to the $0.1 per share recorded for the same in 2025.
PRPO closed Thursday at $28.60, down 0.35%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.